$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx

$swtx Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000177342722000023 Filed on May 05, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$27.37M	$26.45M	$12.38M
YoY Change	121.05%	210.47%	93.44%
% of Gross Profit
Research & Development	$34.10M	$29.34M	$17.38M
YoY Change	96.28%	92.29%	78.63%
% of Gross Profit
Depreciation & Amortization	$108.0K	$146.0K	$110.0K
YoY Change	-1.82%	32.73%	57.14%
% of Gross Profit
Operating Expenses	$61.47M	$55.80M	$29.76M
YoY Change	106.58%	134.63%	84.48%
Operating Profit	-$61.47M		-$29.76M
YoY Change	106.58%		84.48%
Interest Expense	-$139.0K	-$220.0K	-$30.00K
YoY Change	363.33%	-833.33%	-103.57%
% of Operating Profit
Other Income/Expense, Net	$5.000K	-$56.00K	$230.0K
YoY Change	-97.83%	-286.67%	-75.43%
Pretax Income	-$61.80M	-$56.07M	-$29.79M
YoY Change	107.46%	-597.53%	94.83%
Income Tax
% Of Pretax Income
Net Earnings	-$61.80M	-$56.07M	-$29.79M
YoY Change	107.48%	-597.53%	94.76%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.263M	-$1.150M	-$617.7K
COMMON SHARES
Basic Shares Outstanding	48.94M shares	49.25M shares	48.23M shares
Diluted Shares Outstanding	48.94M shares		48.23M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$348.3M	$373.5M	$477.4M
YoY Change	-27.05%	-26.55%	53.46%
Cash & Equivalents	$81.93M	$104.0M	$95.43M
Short-Term Investments	$266.3M	$269.5M	$382.0M
Other Short-Term Assets	$7.680M	$9.409M	$4.100M
YoY Change	87.32%	92.02%	57.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$356.0M	$382.9M	$481.5M
YoY Change	-26.08%	-25.42%	53.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.035M	$3.187M	$1.024M
YoY Change	489.36%	196.47%	13.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.546M	$2.883M	$3.610M
YoY Change	-29.47%	-25.52%	301.11%
Other Assets	$2.627M	$2.709M	$2.547M
YoY Change	3.14%	35.31%	27.35%
Total Long-Term Assets	$49.63M	$69.58M	$73.07M
YoY Change	-32.08%	10.81%	1823.0%
TOTAL ASSETS
Total Short-Term Assets	$356.0M	$382.9M	$481.5M
Total Long-Term Assets	$49.63M	$69.58M	$73.07M
Total Assets	$405.6M	$452.5M	$554.6M
YoY Change	-26.87%	-21.47%	74.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.654M	$3.429M	$2.229M
YoY Change	-25.8%	154.0%	39.31%
Accrued Expenses	$21.26M	$25.38M	$15.26M
YoY Change	39.34%	70.49%	131.15%
Deferred Revenue		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$327.0K	$1.162M	$1.200M
YoY Change	-72.75%	-17.0%
Total Short-Term Liabilities	$23.24M	$29.97M	$18.73M
YoY Change	24.07%	70.18%	117.78%
LONG-TERM LIABILITIES
Long-Term Debt	$5.538M	$129.0K	$1.000M
YoY Change	453.8%	-90.79%
Other Long-Term Liabilities	$5.500M	$0.00	$131.0K
YoY Change	4098.47%	-100.0%	-81.29%
Total Long-Term Liabilities	$5.538M	$0.00	$131.0K
YoY Change	4127.48%	-100.0%	-81.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.24M	$29.97M	$18.73M
Total Long-Term Liabilities	$5.538M	$0.00	$131.0K
Total Liabilities	$28.78M	$30.10M	$19.89M
YoY Change	44.67%	57.31%	113.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$354.3M	-$292.5M	-$148.4M
YoY Change	138.75%	146.63%
Common Stock	$5.000K	$5.000K	$5.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$906.0K	$0.00
YoY Change
Treasury Stock Shares	16.21K shares	0.000 shares
Shareholders Equity	$376.8M	$422.4M	$534.7M
YoY Change
Total Liabilities & Shareholders Equity	$405.6M	$452.5M	$554.6M
YoY Change	-26.87%	-21.47%	74.73%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$61.80M	-$56.07M	-$29.79M
YoY Change	107.48%	-597.53%	94.76%
Depreciation, Depletion And Amortization	$108.0K	$146.0K	$110.0K
YoY Change	-1.82%	32.73%	57.14%
Cash From Operating Activities	-$48.69M	-$46.32M	-$21.10M
YoY Change	130.71%	-407.34%	28.7%
INVESTING ACTIVITIES
Capital Expenditures	$2.387M	-$1.504M	$45.00K
YoY Change	5204.44%	2908.0%	-71.88%
Acquisitions
YoY Change
Other Investing Activities	$28.81M	$57.69M	-$30.87M
YoY Change	-193.33%	-125.9%
Cash From Investing Activities	$26.42M	$56.18M	-$30.92M
YoY Change	-185.46%	-125.22%	19223.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$261.0K	244.0K	$359.0K
YoY Change	-27.3%	-99.91%	5883.33%
NET CHANGE
Cash From Operating Activities	-$48.69M	-46.32M	-$21.10M
Cash From Investing Activities	$26.42M	56.18M	-$30.92M
Cash From Financing Activities	$261.0K	244.0K	$359.0K
Net Change In Cash	-$22.00M	10.11M	-$51.66M
YoY Change	-57.41%	-83.77%	212.13%
FREE CASH FLOW
Cash From Operating Activities	-$48.69M	-$46.32M	-$21.10M
Capital Expenditures	$2.387M	-$1.504M	$45.00K
Free Cash Flow	-$51.08M	-$44.81M	-$21.15M
YoY Change	141.5%	-396.38%	27.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001773427
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-39044
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	SWTX
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	SPRINGWORKS THERAPEUTICS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-4066827
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Washington Blvd
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Stamford
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06902
CY2022Q1	dei	City Area Code CityAreaCode	203
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	883-9490
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49413760	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81933000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103961000	USD
CY2022Q1	us-gaap	Marketable Securities MarketableSecurities	266338000	USD
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	269540000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	7680000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	9409000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	355951000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	382910000	USD
CY2022Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	32475000	USD
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	59230000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6035000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3187000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5356000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1010000	USD
CY2022Q1	us-gaap	Equity Method Investments EquityMethodInvestments	2546000	USD
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	2883000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	590000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	565000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2627000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2709000	USD
CY2022Q1	us-gaap	Assets Assets	405580000	USD
CY2021Q4	us-gaap	Assets Assets	452494000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1654000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3429000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21257000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25378000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	327000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1162000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	23238000	USD
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29969000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5538000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	28776000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	30098000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49423827	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49247985	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49407617	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49247985	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	733477000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	715216000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-354314000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-292513000	USD
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	16210	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	906000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1458000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-312000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	376804000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	422396000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	405580000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	452494000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34103000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17375000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27366000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12381000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	61469000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	29756000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-61469000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-29756000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-193000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	198000	USD
CY2021Q1	us-gaap	Investment Income Net InvestmentIncomeNet	227000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	230000	USD
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-337000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-261000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-61801000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-29787000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.26
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.26
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.62
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.62
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48937756	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48937756	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48229539	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48229539	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-61801000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-29787000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1146000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	12000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1146000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62947000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29775000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	557058000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7055000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	359000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-29787000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	534697000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	422396000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17094000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1167000	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	906000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1146000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-61801000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	376804000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-61801000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-29787000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	108000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	110000	USD
CY2022Q1	swtx	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	272000	USD
CY2021Q1	swtx	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	257000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	17094000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7055000	USD
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-337000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-261000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1729000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-697000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-82000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	545000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1770000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	879000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4695000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	357000	USD
CY2022Q1	swtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-44000	USD
CY2021Q1	swtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-355000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-33000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48688000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21104000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2387000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	USD
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23242000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	86373000	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	52053000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	55500000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26424000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-30918000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	906000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1167000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	359000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	261000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	359000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-22003000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-51663000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104526000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147654000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82523000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95991000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5580000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SpringWorks Therapeutics, Inc., together with its wholly-owned subsidiaries, collectively, the Company, is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Two of the programs are late-stage clinical product candidates: nirogacestat and mirdametinib.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of $354.3 million and $292.5 million, and working capital of $332.7 million and $352.9 million, as of March 31, 2022 and December 31, 2021, respectively. The Company is subject to those risks associated with any biopharmaceutical company that has substantial expenditures for development. There can be no assurance that the Company’s development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, consultants and vendors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash, cash equivalents and marketable securities of $380.7 million and $432.7 million as of March 31, 2022 and December 31, 2021, respectively. Based on the Company's cash, cash equivalents and marketable securities as of March 31, 2022, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve months after the date that these financial statements are issued.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 11, 2020, the World Health Organization designated the outbreak of the disease associated with the novel strain of coronavirus known as COVID-19 as a global pandemic. This disease continues to spread, including recent acceleration of the spread of the Delta and Omicron variants of COVID-19 in the areas in which the Company operates. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets. The global pandemic caused by COVID-19 (including the impact of emerging variant strains of the COVID-19 virus and stagnant vaccination rates) did not have significant impacts on the Company's financial condition, results of operations or cash flows during the periods presented. While the extent to which the ongoing COVID-19 pandemic impacts the Company’s future results will depend on future developments, the pandemic and associated impacts, including the duration, spread and intensity of the pandemic (including any resurgences), the impact of emerging variant strains of the COVID-19 virus and the rollout of COVID-19 vaccines, all of which remain uncertain and difficult to predict, could result in a material impact to the Company’s future financial condition, results of operations and cash flows.</span></div>
CY2022Q1	swtx	Number Of Clinical Trials NumberOfClinicalTrials	2	trial
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-354300000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-292500000	USD
CY2022Q1	swtx	Working Capital WorkingCapital	332700000	USD
CY2021Q4	swtx	Working Capital WorkingCapital	352900000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	380700000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	432700000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	257000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the valuation of stock-based compensation awards. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. </span></div>Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	311364000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1460000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	309906000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	269668000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	131000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	269540000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	975000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1108000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4528000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12081000	USD
CY2022Q1	swtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	12235000	USD
CY2021Q4	swtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	10069000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3519000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2120000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21257000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25378000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1262000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1155000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1184000	USD
CY2022Q1	swtx	Lessee Operating Lease Liability Payments Due After Three Year LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear	2881000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6739000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	874000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5865000	USD
CY2022Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17094000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7055000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8690989	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6378341	shares

Files In Submission

Name	View Source	Status
0001773427-22-000023-index-headers.html	Edgar Link	pending
0001773427-22-000023-index.html	Edgar Link	pending
0001773427-22-000023.txt	Edgar Link	pending
0001773427-22-000023-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
springworks-retentionbonus.htm	Edgar Link	pending
springworks-retentionbonusa.htm	Edgar Link	pending
stamfordsecondleasemodif.htm	Edgar Link	pending
stamfordsecondleasemodif001.jpg	Edgar Link	pending
stamfordsecondleasemodif002.jpg	Edgar Link	pending
stamfordsecondleasemodif003.jpg	Edgar Link	pending
stamfordsecondleasemodif004.jpg	Edgar Link	pending
stamfordsecondleasemodif005.jpg	Edgar Link	pending
stamfordsecondleasemodif006.jpg	Edgar Link	pending
stamfordsecondleasemodif007.jpg	Edgar Link	pending
stamfordsecondleasemodif008.jpg	Edgar Link	pending
stamfordsecondleasemodif009.jpg	Edgar Link	pending
stamfordsecondleasemodif010.jpg	Edgar Link	pending
swtx-20210331xex322.htm	Edgar Link	pending
swtx-20220331.htm	Edgar Link	pending
swtx-20220331.xsd	Edgar Link	pending
swtx-20220331xex311.htm	Edgar Link	pending
swtx-20220331xex312.htm	Edgar Link	pending
swtx-20220331xex321.htm	Edgar Link	pending
swtx-20220331_cal.xml	Edgar Link	unprocessable
swtx-20220331_def.xml	Edgar Link	unprocessable
swtx-20220331_htm.xml	Edgar Link	completed
swtx-20220331_lab.xml	Edgar Link	unprocessable
swtx-20220331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx

2022 Q1 Form 10-Q Financial Statement

#000177342722000023 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWTX SpringWorks Therapeutics, Inc. Stock $swtx

2022 Q1 Form 10-Q Financial Statement

#000177342722000023 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx